This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Mosquirix (with MPL adjuvant)

GlaxoSmithKline plc

Drug Names(s): RTS,S, RTS,S/AS01, RTS,S/AS02, 257049

Description: Developed over the course of two decades, Mosquirix contains a polypeptide chain corresponding to part of the circumsporozoite protein, a major cell-surface protein found on the form of the parasite that is injected into the bloodstream by mosquitoes. This chain is fused to the hepatitis B surface antigen, creating a hybrid molecule called RTS. The vaccine also contains a separate polypeptide (S) corresponding to the hepatitis B surface antigen, as well as proprietary adjuvants developed by GlaxoSmithKline to stimulate an immune response.

Mosquirix contains MPL adjuvant, which is a proprietary form of monophosphoryl lipid A, a derivative of bacterial endotoxin, one of the most potent immunostimulants known. Prepared from a heptoseless mutant of Salmonella minnesota, MPL is chemically similar to lipid A but lacks an acid-labile phosphoryl group and a base-labile acyl group. MPL retains the beneficial biological activities of lipid A but with a safety profile suitable for evaluation in pediatric applications.

MPL may be a key component of vaccines using technologies such as recombinant and synthetic antigens. Although vaccines incorporating these antigens are safer than previous attenuated or killed whole-cell vaccines, many of them are poorly immunogenic in the absence of a potent adjuvant. MPL has demonstrated utility with peptide, bacterial sub-unit and synthetic polysaccharide antigens. Vaccines for infectious diseases and allergy desensitization containing this microbially derived adjuvant have demonstrated safety and efficacy in human clinical trials involving thousands of doses. Humoral, cell-mediated and mucosal immunity can be stimulated by altering formulations and delivery routes.

RTS,S antigen is being tested with two different adjuvants:

  • AS01: liposome formulation with MPL and QS21 immunostimulants;
  • AS02: proprietary oil-in-water emulsion formulated with MPL and Stimulon QS21 immunostimulants

Deal Structure: Corixa and GlaxoSmithKline
In July 2004, Corixa announced an MPL adjuvant manufacturing and supply contract with GSK which provides guaranteed payments to Corixa for supplying GSK with increasing annual quantities of MPL adjuvant. Under the terms of the agreement, Corixa agreed to expand MPL production with anticipated approvals of GSK vaccines that contain MPL. Corixa received a multi-million dollar manufacturing licensing fee from GSK and will receive royalties on the potential sale of all GSK vaccines containing MPL.

In July 2005, Corixa Corporation announced that its stockholders adopted the merger agreement pursuant to which Corixa will be merged with and into a wholly owned subsidiary of SmithKline Beecham Corporation (d/b/a/ GlaxoSmithKline). On April 29, 2005, Corixa and GlaxoSmithKline announced the signing of the merger agreement.

Agenus and GlaxoSmithKline
RTS,S contains Antigenics' QS-21 Stimulon adjuvant. Under the terms of the license and...See full deal structure in Biomedtracker

Partners: Agenus Inc. Oberland Capital Management, LLC


Mosquirix (with MPL adjuvant) News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug